Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.97 |
| ▸ | TTR | P02766 | 3/20 | 0.97 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.97 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.97 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.97 |
| ▸ | ALB | P02768 | 1/20 | 0.97 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.97 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.97 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.97 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.97 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.97 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL996716 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL29354260 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL2799 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL2216520 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22370200 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL1178502 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL40785 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22129258 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL24010 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL4615491 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101433544-B | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use | JIANGSU ZEUKOV PHARMACEUTICAL SCIENCE & TECHNOLOGY INC | 2012-07-18 | — | — | CN | claimed |
| CN-101433544-A | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use | JIANGSU ZEUKOV PHARMACEUTICAL (CN) | 2009-05-20 | — | — | CN | claimed |
| EP-1183015-B1 | MULTILAYERED TABLET FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC | GRUENENTHAL GMBH (DE) | 2004-10-20 | — | — | EP | claimed |
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | NIH - DEITR | 2002-02-07 | — | — | US | claimed |
| WO-2001080896-A2 | FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| US-20230201111-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | THE JOHNS HOPKINS UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| CN-111743878-B | Compositions and methods for ophthalmic and/or other applications | 卡拉制药公司 | 2023-04-11 | — | — | CN | disclosed |
| US-11596599-B2 | Compositions and methods for ophthalmic and/or other applications | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| US-11219597-B2 | Compositions and methods for ophthalmic and/or other applications | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-11219596-B2 | Compositions and methods for ophthalmic and/or other applications | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210386661-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | THE JOHNS HOPKINS UNIVERSITY | 2021-12-16 | — | — | US | disclosed |
| US-20210228482-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | THE JOHNS HOPKINS UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| US-20100015049-A1 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010009116-A2 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009118764-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DICLOFENAC AND PARACETAMOL | PANACEA BIOTEC LIMITED (IN) | 2009-10-01 | — | — | WO | disclosed |
| CN-101433544-A | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use | JIANGSU ZEUKOV PHARMACEUTICAL (CN) | 2009-05-20 | — | — | CN | disclosed |
| US-20010029269-A1 | Ophthalmic compositions | INSITE VISION INCORPORATED | 2001-10-11 | — | — | US | disclosed |
| US-6265444-B1 | AQUEOUS SOLUTION OF A NON-STEROID ANTIINFLAMMATORY DRUG | INSITE VISION INCORPORATED | 2001-07-24 | — | — | US | disclosed |
| EP-0983073-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A DIVALENT SALT AND A NON STEROIDAL ANTI-INFLAMMATORY DRUGS AS A PRECIPITATE | INSITE VISION INCORPORATED (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052579-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A DIVALENT SALT AND A NON STEROIDAL ANTI-INFLAMMATORY DRUGS AS A PRECIPITATE | INSITE VISION INCORPORATED (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | UGT1A1, UGT1A3, CYP7A1 | PTGS2 1380/4885PTGS1 1009/4885CXCL8 3199/4885 |
| US-11219597-B2 | Compositions and methods for ophthalmic and/or other applications | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-20230201111-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-11219596-B2 | Compositions and methods for ophthalmic and/or other applications | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-11596599-B2 | Compositions and methods for ophthalmic and/or other applications | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-20100015049-A1 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | PTGES3, PTGS1, PTGES | PTGS2 8/4885PTGS1 2/4885CXCL8 20/4885 |
| US-20210228482-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-20210386661-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | MUC1, PDE6C, STRA6 | PTGS2 2225/4885PTGS1 2063/4885CXCL8 477/4885 |
| US-20010029269-A1 | Ophthalmic compositions | PLA2G12B, PRDX6, ORAI1 | PTGS2 235/4885PTGS1 96/4885CXCL8 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.